NEW YORK (GenomeWeb) – Canaccord Genuity has upgraded its rating for Genomic Health to Buy from Hold, the investment banking company said today.

After surveying and interviewing urologists, Canaccord analyst Mark Massaro wrote in his note, the bank found that Genomic Health has the best brand awareness for its cancer tests. "To our surprise, more docs responded they are aware of GHDX's test over MYGN's test, despite MYGN's first mover advantage, which we think is a testament to GHDX's solid early marketing and commercial initiatives," he added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.